Tag Archives: targeted cancer therapy

As cancer treatment becomes increasingly sophisticated, clinicians are encountering a growing metabolic challenge. Cancer therapy–induced hyperglycemia has emerged as an important concern with the expanding use of immunotherapies and targeted therapies. In some patients, hyperglycemia develops gradually. In others, particularly those receiving immune checkpoint inhibitors, severe diabetes and diabetic ketoacidosis …

Cancer treatment is evolving rapidly, and with that progress comes a new challenge for clinicians managing glucose disorders. As immune checkpoint inhibitors (ICIs) and PI3K inhibitors become more widely used in oncology, therapy-related hyperglycemia is appearing more often in clinical practice. Many patients receiving cancer treatment now face unexpected glucose …